Cancer drug shows promise for treating stroke

“A big challenge in treating stroke is understanding how other health conditions affect recovery,” said Craig Brown, a neuroscientist in UVic’s Division of Medical Sciences “Many diseases increase the chances of having a stroke, and they also limit recovery. Diabetes is one of these diseases.

"Much like a poker hand, the unique collection of health concerns a patient holds in their hand likely dictates how they should be treated.”

The reasons behind the poorer prognosis for stroke recovery are unknown. However Brown’s neurobiology lab is providing new clues.

“What we’ve found is that diabetic mice have leakier blood vessels in the brain after stroke than mice without diabetes. These leakier vessels lead to greater movement of proteins and other damaging elements of blood plasma into the brain, a process that is normally regulated in a strict manner to protect brain health,” said Brown.

The study traces the cause of leaky vessels to excessive vascular endothelial growth factor (VEGF) signaling, which regulates the growth and permeability of blood vessels. Fortunately, several drugs, known as VEGF inhibitors, have been developed over the last few decades to block cancerous tumours from growing new blood vessels and spreading.

Brown’s lab used one of these cancer drugs in mouse models to see if they could reduce blood vessel leakage and the damaging effects of stroke.

The treatment not only helped reduce the leakiness of blood vessels, but it also prevented the loss of neural connections and improved the recovery of sensory-motor function—a discovery that could lead to better recovery rates for diabetic patients.

Quite surprisingly, however, the same treatment had no benefits in non-diabetic mice.

The study’s results were published in The Journal of Neuroscience.

For more information on Brown and his research is available here. Watch a video of Brown talking about his field of research here.